Hims & Hers Health Earnings Preview: Q2 Expectations, Wall Street Concerns

Hims & Hers Health (HIMS) is set to report Q2 earnings on August 4, with expectations of a 150% YoY EPS growth and a 75% sales increase to $551.67 million. TD Cowen analyst Jonna Kim reiterated a Hold rating and raised the price target to $43 from $38, expecting Q2 sales growth to beat the Street's estimate. TipRanks' AI analyst has assigned an Outperform rating with a price target of $57, while options traders anticipate a major move on the stock immediately after the earnings report.

Hims & Hers Health (HIMS) is poised to release its second-quarter (Q2) 2025 earnings on August 4. Analysts anticipate a significant year-over-year (YoY) earnings per share (EPS) growth of 150% and a 75% increase in sales to $551.67 million. TD Cowen analyst Jonna Kim reiterated a Hold rating but raised the price target to $43 from $38, expecting Q2 sales growth to beat the Street's estimate. TipRanks' AI analyst assigned an Outperform rating with a price target of $57, while options traders anticipate a major move on the stock immediately following the earnings report.

The company has consistently demonstrated strong market acceptance of its health and wellness products and services. In the first quarter of 2025, HIMS ended with nearly 2.4 million subscribers, representing a 38.4% increase year over year. Monthly online revenue per average subscriber increased 52.7% year over year, primarily driven by subscriber uptake of its GLP-1 weight loss offering and changes in product mix [2].

HIMS' earnings per share (EPS) of 20 cents in the last reported quarter exceeded the Zacks Consensus Estimate by 66.7%. Over the trailing four quarters, the company's earnings outperformed the Zacks Consensus Estimate on two occasions, missed once, and broke even in the other, delivering an average earnings surprise of 19.6% [2].

Analysts expect HIMS' Q2 2025 revenue to reach $551.8 million, a 74.8% improvement over the prior-year quarter's reported figure. The consensus estimate for EPS is pegged at 18 cents, indicating a surge of 200% from the prior-year period's reported number [2].

HIMS' share price performance has been robust, with shares gaining 81.4% over the past three months, outperforming the Medical Info Systems industry's growth of 5.1%. The company's forward 12-month price-to-sales (P/S) ratio of 5.1X is a discount to the industry average of 5.8X, suggesting that investors may be paying a lower price relative to the company's expected sales growth [2].

Management has indicated plans to expand into new specialties that deeply impact people's lives, with offerings in low testosterone and menopause support expected to launch this year. Longer-term opportunities in longevity, sleep, and preventative care are also emerging, positioning HIMS for continued growth.

References:
[1] https://finviz.com/news/120829/hims-hers-health-inc-hims-is-attracting-investor-attention-here-is-what-you-should-know
[2] https://www.nasdaq.com/articles/can-sustained-product-demand-drive-hims-stock-q2-earnings